PDS Biotechnology Corp PDSB:NASDAQ

Last Price$3.69Cboe Real-Time Last Sale as of 10:39AM ET 6/30/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(2.38%)
Bid (Size)$3.65 (1,000)
Ask (Size)$3.73 (1,300)
Day Low / High$3.65 - 3.75
Volume44.6 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022

 

PDS Biotechnology Corp ( NASDAQ )

Price: $3.69
Change: -0.09 (2.38%)
Volume: 44.6 K
10:39AM ET 6/30/2022
 
 

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $1.94
Change: -0.07 (3.48%)
Volume: 21.9 K
10:31AM ET 6/30/2022
 
 

Dare Bioscience Inc ( NASDAQ )

Price: $1.24
Change: -0.01 (0.80%)
Volume: 1.3 M
10:40AM ET 6/30/2022
 
 

RVL Pharmaceuticals PLC ( NASDAQ )

Price: $1.34
Change: +0.02 (1.52%)
Volume: 1.5 K
3:52PM ET 6/29/2022
 
 

Gamida Cell Ltd ( NASDAQ )

Price: $1.72
Change: -0.01 (0.58%)
Volume: 74.1 K
10:35AM ET 6/30/2022
 

Read more news Recent News

PDS Biotechnology Secures FDA's Fast Track Designation for Combination Therapy for Head, Neck Cancer; Shares Climb
10:06AM ET 6/02/2022 MT Newswires

PDS Biotechnology (PDSB) said Thursday that the US Food and Drug Administration has granted fast track designation to its lead candidate PDS0101 in...

Alliance Global Adjusts Price Target on PDS Biotechnology to $16 From $18, Reiterates Buy Rating
5:42AM ET 5/16/2022 MT Newswires

PDS Biotechnology (PDSB) has an average rating of buy and price targets ranging from $15 to $25, according to analysts polled by Capital IQ. (MT Newswires...

PDS Biotechnology Says Data Showed PDS0101, Keytruda Combination to Treat Cancer is Likely Safe; Shares Rise
12:58PM ET 2/24/2022 MT Newswires

PDS Biotechnology (PDSB) said Thursday preliminary data showed that PDS0101 in combination with Merck's (MRK) Keytruda to treat head and neck cancer is...

PDS Biotechnology Launches Clinical Trial for Head, Neck Cancer Treatment; Shares Gain
9:51AM ET 2/15/2022 MT Newswires

PDS Biotechnology (PDSB) said Tuesday it has launched a clinical trial of PDS0101 for the treatment of patients with human papillomavirus-associated...

Company Profile

Business DescriptionPDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ. View company web site for more details
AddressFlorham Park
Princeton, New Jersey 07932
Phone+1.800.208.3343
Number of Employees10
Recent SEC Filing06/29/20224
President, Chief Executive Officer & DirectorFrank K. Bedu-Addo
Chief Financial & Accounting OfficerMatthew C. Hill
Chief Medical OfficerLauren V. Wood
Chief Scientific OfficerGregory L. Conn

Company Highlights

Price Open$3.71
Previous Close$3.78
52 Week Range$2.91 - 17.85
Market Capitalization$105.0 M
Shares Outstanding28.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.82
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-34.38%

Analyst Ratings as of 09/15/2021

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset